Evidence map›Paper›PMID 25826224›Full record

ReviewBritish journal of cancer2015

Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.

T Kimhofer, H Fye, S Taylor-Robinson, M Thursz, E Holmes

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 118 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Blood biomarkers of hepatocellular carcinoma: a critical review.Frontiers in cell and developmental biology · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Antitumor effect and metabonomics of niclosamide micelles.Journal of cellular and molecular medicine · 2022
    Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

T KimhoferFaculty of Medicine, Department of Surgery and Cancer, Imperial College London, 661 Sir Alexander Fleming Building, South Kensington Campus, London SW7 2AZ, UK.
H FyeMRC Unit (UK), The Gambia Laboratories, PO Box 273, Fajara, Atlantic Boulevard, The Gambia.
S Taylor-RobinsonLiver Unit, Division of Diabetes Endocrinology and Metabolism, Department of Medicine, Imperial College London, 10th Floor QEQM Building, St Mary's Hospital Campus, South Wharf Road, London W2 1NY, UK.
M ThurszLiver Unit, Division of Diabetes Endocrinology and Metabolism, Department of Medicine, Imperial College London, 10th Floor QEQM Building, St Mary's Hospital Campus, South Wharf Road, London W2 1NY, UK.
E HolmesFaculty of Medicine, Department of Surgery and Cancer, Imperial College London, 661 Sir Alexander Fleming Building, South Kensington Campus, London SW7 2AZ, UK.
MRC Unit the Gambia · GM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) ranks third in overall global cancer-related mortality. Symptomatic presentation often means advanced disease where potentially curative treatment options become very limited. Numerous international guidelines propose the routine monitoring of those with the highest risk factors for the condition in order to diagnose potential tumourigenesis early. To aid this, the fields of metabonomic- and proteomic-based biomarker discovery have applied advanced tools to identify early changes in protein and metabolite expression in HCC patients vs controls. With robust validation, it is anticipated that from these candidates will rise a high-performance non-invasive test able to diagnose early HCC and related conditions. This review gathers the numerous markers proposed by studies using mass spectrometry and proton nuclear magnetic resonance spectroscopy and evaluates areas of consistency as well as discordance.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularHumansLiver NeoplasmsMetabolomicsProteomicsBiomarkers, Tumor

Identifiers

PMID25826224
PMCPMC4385954
OpenAlexW2030474140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.